Navigation Links
Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership
Date:2/4/2009

LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary of Schering-Plough, to develop a 'proof of concept' vaccine against the Chikungunya virus. This vaccine aims to reduce the rate of Chikungunya infections.

Viral disease epidemics have increased in incidence around the world in recent decades. One of these diseases is caused by the Chikungunya virus, which is transmitted by mosquitoes. Originally, the disease was confined to Africa, but later spread to countries in Asia. Several cases of this disease have now been confirmed in various European countries. It appears to be spread by travelers returning from affected countries. In France, there have been more than one hundred cases and in Italy a few hundred. It seems evident that the mosquitoes able of transmitting this disease are also present in Europe. Whether or not the virus will spread further throughout Europe remains to be seen.

Virologist Ab Osterhaus, one of the research supervisors, says: "Considering the increasing spread of the Chikungunya virus in Asia, and probably also in Europe in the future, it is important to develop a vaccine against this virus that can be used not only to protect people living in the endemic area, but also travelers traveling to those areas.

The groups that are going to work together in this project have extensive expertise in the field of exotic viral infectious diseases as well as significant experience with the newest technologies in the field of vaccine development."

This TI Pharma project has a budget of EUR 2.3 million and aims to achieve a 'proof of concept' vaccine by the year 2012.

Chikungunya is a serious viral illness, which is transmitted by the Asian tiger mosquito. The disease causes a sudden high fever, a rash and intense joint pain, which can result in disability, which can last several months. There is currently no vaccine or treatment available to combat this disease.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):